Pershing Square Capital
View Older Stories View More Recent Stories
-
CP to address financial community on December 16
-
Valeant Pharma (VRX) CEO Pearson Says Walgreens Deal 'More than Replaces' Philidor
-
Kiva Launches Kiva NYC To Grow Local Small Business
-
Pershing Square Holdings, Ltd. Releases Regular Weekly Net Asset Value as of December 8 2015
-
Ackman plays big role in laying out Canadian Pacific rail deal
-
CP says willing to take Norfolk bid to shareholders
-
CP (CP) CEO and Bill Ackman to Address Investment Community on Tuesday
-
Form SC 13D/A Platform Specialty Produ Filed by: Pershing Square Capital Management, L.P.
-
Norfolk Southern (NSC) Board Rejects Unsolicited Offer from Canadian Pacific (CP)
-
Norfolk Southern Board Of Directors Unanimously Rejects Unsolicited Indication Of Interest From Canadian Pacific
-
Ca Nurses: Elect Gavin Newsom as Our Next Governor
-
Pershing Square Holdings, Ltd. Releases Monthly Net Asset Value and Performance Report for November 2015
-
Ackman's Pershing Square off 15 percent for the year: source
-
Exclusive: Fidelity star Danoff grows cautious about unicorn phenomenon
-
Exclusive: Fidelity star Danoff grows cautious about unicorn phenomenon
-
Exclusive: Fidelity star Danoff grows cautious about unicorn phenomenon
-
Pershing Square Holdings, Ltd. Releases Regular Weekly Net Asset Value as of November 24 2015
-
Herbalife, CEO prevail in 'pyramid scheme' lawsuit
-
Peltz's activist fund Trian to end quarterly redemptions: sources
-
Bill Ackman 'has killed Pershing Square. Its over'- Hempton (VRX)
-
Ackman boosts stake in drugmaker Valeant
-
Pershing Square Capital Affirms Lifting Valeant Pharma (VRX) Stake to 9.9%
-
Market Wrap: Pfizer, Allergan Make it Offiical; Icahn Gets Active on Xerox; Existing Sales Slump in Oct.
-
Pershing Square Holdings, Ltd. Increases Position In Valeant Pharmaceuticals International
-
Ackman's Pershing Square Capital Raises Stake in Valeant Pharmaceuticals (VRX) to 9.9%
-
Ackman's Pershing Square Moves Stake in Valeant Pharma (VRX) to 9.9%
-
Pershing Square Capital Raises Stake in Valeant Pharma (VRX) to 9.9%
-
Form SC 13D/A Valeant Pharmaceuticals Filed by: Pershing Square Capital Management, L.P.
-
Hedge funds' favorite stocks lag broader market: Goldman data
-
Ackman's Pershing Square Holdings off 24.5 percent YTD
-
Pershing Square Holdings, Ltd. Releases Regular Weekly Net Asset Value as of November 17 2015
-
Pershing Square Scholarship winners announced for the Oxford 1+1 MBA
-
Norfolk Southern hostile to Canadian Pacific's $28.4 billion bid
-
Prominent funds piled into Valeant ahead of tailspin
-
Ackman's Pershing Square 13F Shows 43.37M Stake in Mondelez (MDLZ), Maintained Air Products (APD), Canadian Pacific (CP), Valeant (VRX)
-
Form 13F-HR Pershing Square Capital For: Sep 30
-
Pershing Square Holdings, Ltd. Releases Regular Weekly Net Asset Value as of November 10 2015
-
Pershing Square Holdings, Ltd. Publishes Its Third Quarter Interim Management Statement
-
Ackman's Pershing Square Down 2.8% MTD, 21.2% YTD
-
Valeant, Ackman must face U.S. insider trading lawsuit
-
Ackman says Valeant stock 'extraordinary bargain'
-
Ackman says Valeant likely to pay down debt in the next 18 months
-
Big bets on Valeant hit some hedge funds hard in October
-
Pershing Square Holdings, Ltd. Releases Communication From Bill Ackman to Valeant Pharmaceuticals International CEO Mike Pearson
-
Ackman, in email, says supports Valeant CEO Pearson
-
FIRST ® Honors Michael Bloomberg, will.i.am, and Diana Lee Guzman for Advancing STEM Education in Underserved Communities During Inaugural FIRST, Inspire Award and Charity Event
-
Ackman backs Valeant CEO as shares tumble to 2-1/2 year lows
-
Hedge fund Marcato gains 8.4 percent in October: source
-
Valeant's crisis fuels feud between Ackman and Australian fund manager Hempton
-
Ackman's fund lost 7.3 percent in October, off 19 percent for year

